James Smithy
Vice Chair, Quality Assessment, Cellular Therapy Service · New York Presbyterian Hospital
Credentials: · · · · · ·
History
PresentQuality Assessment · New York Presbyterian Hospital
2013–2017
Research
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
JAMA Oncology · 2017 · 169 citations
Circulation Heart Failure · 2019 · 153 citations
Clinical Cancer Research · 2019 · 142 citations

20 papers
- AS
13 papers

9 papers
- DR
8 papers

7 papers
- PM
7 papers

6 papers

5 papers
Clinical trials
- 2024–2027
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
- 2023–2027
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center


